Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Interest & Investment Income (2016 - 2025)

KalVista Pharmaceuticals' Interest & Investment Income history spans 11 years, with the latest figure at $2.0 million for Q2 2025.

  • On a quarterly basis, Interest & Investment Income rose 31.66% to $2.0 million in Q2 2025 year-over-year; TTM through Apr 2025 was $6.6 million, a 68.22% increase, with the full-year FY2025 number at $6.4 million, up 65.17% from a year prior.
  • Interest & Investment Income hit $2.0 million in Q2 2025 for KalVista Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for KALV hit a ceiling of $2.0 million in Q2 2025 and a floor of $137000.0 in Q1 2021.
  • Historically, Interest & Investment Income has averaged $1.1 million across 4 years, with a median of $1.1 million in 2023.
  • Biggest five-year swings in Interest & Investment Income: crashed 63.17% in 2021 and later surged 83.32% in 2024.
  • Tracing KALV's Interest & Investment Income over 4 years: stood at $137000.0 in 2021, then surged by 466.42% to $776000.0 in 2023, then soared by 74.87% to $1.4 million in 2024, then surged by 46.79% to $2.0 million in 2025.
  • Business Quant data shows Interest & Investment Income for KALV at $2.0 million in Q2 2025, $1.4 million in Q4 2024, and $1.7 million in Q3 2024.